Asset profile
VTX3232
Small molecule
Evidence outlook · lead readout
NCT06771115 · Obesity
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT06771115: The study randomized 176 participants and used quadruple masking of the VTX3232 or placebo tablets, with placebo-controlled comparison groups; however, the primary safety endpoint has no posted results. Because the trial’s outcome is currently unknown, the evidence remains limited despite its controlled design.
Also in development:Parkinson's Disease · Phase 2
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.